MAP2K7 and melanoma: We exposed a panel of 16 BRAFV600E/D melanoma cell lines and a batch of non-transformed human primary epidermal melanocytes to the Braf inhibitor vemurafenib (at 100 nM), alone or in combination with the Mek inhibitor trametinib (at 10 nM).